

From: [Trials](#)
To: [Nate Luman](#); [Agarwal, Isha](#); [Sukduang, Sanya](#); [Cousin, Jonathan](#); [Davies, Jonathan](#); [z/Ellodi_IPR](#); [2esf](#); [2Pjm](#); [BoxFalkPharma](#)
Cc: [Trials](#)
Subject: RE: IPR2025-00052/54/55/56 and PGR2025-00086 - joint email regarding related matters
Date: Thursday, January 29, 2026 8:43:09 AM
Attachments: [image001.png](#)

Counsel,

Petitioner is authorized to file the adverse judgments as exhibits in PGR2025-00086. No briefing is authorized at this time.

Regards,

Andrew Kellogg,
Deputy Chief Clerk, Trials
Patent Trial and Appeal Board
USPTO
andrew.kellogg@uspto.gov
(571) 272-5366

PGR2025-00086
Ex. 3103



From: Nate Luman <Nate.Luman@knobbe.com>
Sent: Tuesday, January 27, 2026 12:17 PM
To: Director_DI <Director_DI@uspto.gov>
Cc: Agarwal, Isha <iagarwal@cooley.com>; Sukduang, Sanya <ssukduang@cooley.com>; Cousin, Jonathan <jcousin@cooley.com>; Davies, Jonathan <jdavies@cooley.com>; z/Ellodi_IPR <Ellodi_IPR@cooley.com>; 2esf <2esf@knobbe.com>; 2Pjm <2Pjm@knobbe.com>; BoxFalkPharma <BoxFalkPharma@knobbe.com>
Subject: IPR2025-00052/54/55/56 and PGR2025-00086 - joint email regarding related matters

You don't often get email from nate.luman@knobbe.com. [Learn why this is important](#)

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.
IPR2025-00052/54/55/56 and PGR2025-00086

Dear Honorable Director,

This email is pursuant to Director Stewart's September 16, 2025 Memorandum and the Board's General Order in IPR2025-00052 (Paper 17), IPR2025-00054 (Paper 18), IPR2025-00055 (Paper 17), and IPR2025-00056 (Paper 18) directing the parties to jointly inform the PTAB of any developments regarding adjudication of patentability of substantially similar patent claims that may affect a decision in a related matter identified under 37 C.F.R. § 42.8(b) (2).

The parties jointly inform the PTAB that Adverse Judgment has been entered against Patent Owner in each of IPR2025-00052, IPR2025-00054, IPR2025-00055, and IPR2025-00056, which may affect a decision in the related matter of PGR2025-00086. If so directed, Petitioner can file the Adverse Judgments in the docket of PGR2025-00086.

Additionally, it is Patent Owner's position that it requested adverse judgment in IPR2025-00052, IPR2025-00054, IPR2025-00055, and IPR2025-00056 for resource purposes, and there has been no adjudication on the merits of the patentability of the claims in those proceedings. Further, to the extent Petitioner asserts that the challenged claims in PGR2025-00086 are "substantially similar patent claims" to those that have been disclaimed, Patent Owner disputes this characterization and maintains that the claims are patentably distinct.

Respectfully submitted,
Nathanael Luman
Counsel for Petitioner

Nathanael R. Luman, Ph.D.

Partner

Nate.Luman@knobbe.com

858-707-4235 Direct

Knobbe Martens

3579 Valley Centre Drive, Suite 300

San Diego, CA 92130

www.knobbe.com/nate-luman

NOTICE: This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.